Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
M
MEM
vs
S
S&P/ASX 300
Over the past 12 months, MEM has significantly outperformed S&P/ASX 300, delivering a return of +25% compared to S&P/ASX 300's 0% drop.
Stocks Performance
MEM vs S&P/ASX 300
Performance Gap
MEM vs S&P/ASX 300
Performance By Year
MEM vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Memphasys Ltd
Glance View
Memphasys Ltd. is a life sciences company, which engages in the development and commercialization of novel reproduction and fertility solutions for humans and animals. The company is headquartered in Homebush West, New South Wales. The company went IPO on 2007-05-14. The firm is engaged in developing medical devices, diagnostics, and media with application to assisted reproductive technology (ART) in humans and animals. The firm's product pipeline includes Felix, RoXsta, and AI-Port. Its advanced product, the Felix System, is a patented automated device for quickly and gently separating sperm from a semen sample for use in ART procedures. The Felix device consists of two main components: a console, which supplies electrical power, and a sterile disposable cartridge for sperm isolation and selection. RoXsta is an in-vitro diagnostic device that assesses semen and other bodily fluids for oxidative stress load. RoXsta also has an application as part of a suite of products that can support the animal industry. AI-Port has been developed for the purpose of maintaining the viability of livestock semen for up to seven days at a temperature range of 22 - 25 degrees Celsius.